Lu AA24530

From Self-sufficiency
Jump to: navigation, search
Lu AA24530
Systematic (IUPAC) name
?
Identifiers
CAS Number ?
ATC code none
PubChem CID ?
Chemical data
Formula ?
Molar mass ?
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lu AA24530 is a antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder.[1][2] As of March 2010 it is in phase III clinical trials.[3] Lu AA24530 acts as a monoamine reuptake inhibitor (reportedly serotonin according to one source), 5-HT2C receptor antagonist, and 5-HT3 receptor antagonist.[4][5] An NDA is not expected to be submitted to the FDA until at least 2012.[1]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)


35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
  1. ↑ 1.0 1.1 "Development programme - Lundbeck". 
  2. ↑ "Search of: Lu AA24530 - List Results - ClinicalTrials.gov". 
  3. ↑ "Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 (March 3, 2010) | 2010 | Newsroom | Takeda Pharmaceutical Company Limited". 
  4. ↑ "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech". 
  5. ↑ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Lu_AA24530&oldid=22777"